AIVITA Biomedical is a biotechnology company developing personalized vaccines for the prevention of COVID-19 and treatment of cancer. We target the seed of all cancers: tumor-initiating cells, using a unique pan-antigenic approach. By targeting all neoantigens, rather than a select few, our treatment overcomes cancer’s tendency to mutate over time. Our personalized COVID-19 vaccine can be rapidly adapted and scaled to meet any emerging viral mutations. We owe these innovations to our unique expertise in stem cell growth and directed, high-purity differentiation which enables us to develop safe, efficient and economical manufacturing processes for therapeutic development.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Platform vaccine for treatment of multiple cancers, and now COVID-19
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):